Goodrich Katherine sold $183K of TARS
Goodrich Katherine sold 2,954 shares of Tarsus Pharmaceuticals, Inc. (TARS) at $62.08 ($0.18M total) on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price, and that it was executed under a pre-arranged Rule 10b5-1 plan; there is no accompanying operational or financial update.
Market read
Traders may treat this as routine insider liquidity disclosure with limited directional implications absent other catalysts.
What to watch
The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total holdings beyond the post-transaction share count.
Background
This is an SEC Form 4 insider transaction for Tarsus Pharmaceuticals, Inc., reported by director Katherine Goodrich.
Ticker impact
Tarsus Pharmaceuticals director Katherine Goodrich sold 2,954 shares at $62.08 via an open-market sale under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4 sale.
The filing is an insider transaction disclosure, not earnings, guidance, or a business-changing event; 10b5-1 plans typically reduce interpretive value.
Market effects
Minimal, as the disclosure does not indicate sector-wide regulatory, clinical, or commercial changes.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, unusually large or clustered insider selling can sometimes coincide with private information; traders may still monitor for follow-on sales or buys.
Key entities
- issuerTarsus Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderKatherine Goodrich
Director who sold shares in an open-market transaction under a 10b5-1 plan.
